Bristol-Myers Squibb Company (BMY) vs Eli Lilly and Company (LLY)
A side-by-side comparison of Bristol-Myers Squibb Company and Eli Lilly and Company across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 10, 2026. Differences are shown without an overall score or investment verdict.
BMY
Bristol-Myers Squibb Company
$63.64HealthcareDelayed quote: Sep 11, 2026, 4:00 PM EDT
LLY
Eli Lilly and Company
$1,115.25HealthcareDelayed quote: Sep 11, 2026, 3:59 PM EDT
Total return — BMY vs LLY
growth of $100 · dividends reinvested · last 10yBMY +60.4% (+4.8%/yr)LLY +1566.6% (+32.5%/yr)LLY compounded faster over this window
Log scale — wide-divergence pair
BMY LLY
BMY vs LLY: by the numbers
- •LLY is the larger company ($1.05T vs $130.00B market cap).
- •BMY trades at the lower trailing earnings multiple (14.02 vs 37.42 P/E), one valuation lens rather than an overall verdict.
- •LLY converts more revenue to profit (33.53% vs 18.87% net margin).
- •LLY grew revenue faster over the past five years (24.42% vs 2.08% CAGR).
- •BMY pays the higher dividend yield (3.94% vs 0.60%).
Metrics side by side
Valuation
| Metric | BMY | LLY |
|---|---|---|
| P/E ratio | 14.02 | 37.42 |
| Forward P/E | 9.18 | 30.64 |
| P/S ratio | 2.64 | 13.18 |
| P/B ratio | 5.82 | 31.00 |
| EV / EBITDA | 9.71 | 29.91 |
| FCF yield | 8.80% | 1.91% |
Profitability
| Metric | BMY | LLY |
|---|---|---|
| Gross margin | 70.16% | 84.01% |
| Operating margin | 28.27% | 43.92% |
| Net margin | 18.87% | 33.53% |
| ROE | 41.59% | 78.84% |
| ROIC | 15.47% | 27.38% |
Dividends
| Metric | BMY | LLY |
|---|---|---|
| Dividend yield | 3.94% | 0.60% |
| Payout ratio | 55.29% | 22.45% |
Growth (annualized)
| Metric | BMY | LLY |
|---|---|---|
| Revenue CAGR (5Y) | 2.08% | 24.42% |
| EPS CAGR (5Y) | 9.38% | 28.88% |
| FCF CAGR (5Y) | -0.95% | 32.91% |
| Total return CAGR (5Y) | 4.39% | 37.46% |
Frequently asked
- Which has the lower trailing P/E, BMY or LLY?
- BMY has the lower trailing P/E: BMY trades at 14.02 and LLY at 37.42. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, BMY or LLY?
- Over the past five years, LLY grew revenue faster — BMY at a 2.08% CAGR versus LLY at 24.42%.
- Does BMY or LLY pay a bigger dividend?
- BMY yields 3.94% and LLY yields 0.60% based on trailing dividends and the latest price.
- Is BMY or LLY more profitable?
- LLY runs the higher net margin — BMY at 18.87% versus LLY at 33.53%.
- How have BMY and LLY total returns compared?
- Over the past 10 years, BMY delivered 5.01% and LLY delivered 32.58% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bristol-Myers Squibb P/E ratioEli Lilly P/E ratioBristol-Myers Squibb dividend yieldEli Lilly dividend yieldBristol-Myers Squibb ROEEli Lilly ROEBristol-Myers Squibb operating marginEli Lilly operating marginBristol-Myers Squibb revenue growthEli Lilly revenue growthBristol-Myers Squibb free cash flowEli Lilly free cash flow
Bristol-Myers Squibb & Eli Lilly appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 10, 2026.